United-Guardian (UG)
Market Price (6/28/2026): $7.04 | Market Cap: $32.3 MilSector: Consumer Staples | Industry: Household Products
United-Guardian (UG)
Market Price (6/28/2026): $7.04Market Cap: $32.3 MilSector: Consumer StaplesIndustry: Household Products
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 14%, Dividend Yield is 7.0%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 9.7%, FCF Yield is 6.6% Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -24% Attractive operating marginsOp Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 21% Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 21%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 20% Low stock price volatilityVol 12M is 36% Megatrend and thematic driversMegatrends include Health & Wellness Trends, Advanced Materials, and Aging Population & Chronic Disease. Themes include Organic & Natural Products, Show more. | Weak multi-year price returns2Y Excs Rtn is -46%, 3Y Excs Rtn is -69% | Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -4.1%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -1.3% Key risksUG key risks include [1] severe dependence on its sharply declining cosmetic ingredients segment, Show more. |
| Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 14%, Dividend Yield is 7.0%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 9.7%, FCF Yield is 6.6% |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -24% |
| Attractive operating marginsOp Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 21% |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 21%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 20% |
| Low stock price volatilityVol 12M is 36% |
| Megatrend and thematic driversMegatrends include Health & Wellness Trends, Advanced Materials, and Aging Population & Chronic Disease. Themes include Organic & Natural Products, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -46%, 3Y Excs Rtn is -69% |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -4.1%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -1.3% |
| Key risksUG key risks include [1] severe dependence on its sharply declining cosmetic ingredients segment, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Updated on 6/1/2026
United-Guardian (UG) stock has gained about 5% since 2/28/2026 because of the following key factors:
1. United-Guardian reported strong first-quarter 2026 financial results, with net income surging by 46.0% year-over-year to $818,902, translating to earnings per share (EPS) of $0.18, up from $0.12 in Q1 2025.
2. The company experienced robust sales growth in its key business segments, with overall net sales increasing by 15.8% year-over-year to $2,872,222 in Q1 2026. Pharmaceutical sales rose by 24%, primarily driven by increased demand for Renacidin®, while cosmetic ingredient sales grew by 21%, largely due to a 45% increase in purchases from its largest distributor, Ashland Specialty Ingredients, as excess inventory was depleted.
Show more
United-Guardian (UG) stock has gained about 5% since 2/28/2026 because of the following key factors:
1. United-Guardian reported strong first-quarter 2026 financial results, with net income surging by 46.0% year-over-year to $818,902, translating to earnings per share (EPS) of $0.18, up from $0.12 in Q1 2025.
2. The company experienced robust sales growth in its key business segments, with overall net sales increasing by 15.8% year-over-year to $2,872,222 in Q1 2026. Pharmaceutical sales rose by 24%, primarily driven by increased demand for Renacidin®, while cosmetic ingredient sales grew by 21%, largely due to a 45% increase in purchases from its largest distributor, Ashland Specialty Ingredients, as excess inventory was depleted.
Show more
Updated on 6/1/2026
United-Guardian (UG) stock has gained about 5% since 2/28/2026 because of the following key factors:
1. United-Guardian reported strong first-quarter 2026 financial results, with net income surging by 46.0% year-over-year to $818,902, translating to earnings per share (EPS) of $0.18, up from $0.12 in Q1 2025.
2. The company experienced robust sales growth in its key business segments, with overall net sales increasing by 15.8% year-over-year to $2,872,222 in Q1 2026. Pharmaceutical sales rose by 24%, primarily driven by increased demand for Renacidin®, while cosmetic ingredient sales grew by 21%, largely due to a 45% increase in purchases from its largest distributor, Ashland Specialty Ingredients, as excess inventory was depleted.
3. United-Guardian's Q1 2026 income was positively impacted by a one-time settlement of $303,133. This income was recognized from a contract manufacturer of Renacidin, related to an unexpected facility shutdown in late 2023 that had resulted in lost sales.
Show less
United-Guardian (UG) stock has gained about 5% since 2/28/2026 because of the following key factors:
1. United-Guardian reported strong first-quarter 2026 financial results, with net income surging by 46.0% year-over-year to $818,902, translating to earnings per share (EPS) of $0.18, up from $0.12 in Q1 2025.
2. The company experienced robust sales growth in its key business segments, with overall net sales increasing by 15.8% year-over-year to $2,872,222 in Q1 2026. Pharmaceutical sales rose by 24%, primarily driven by increased demand for Renacidin®, while cosmetic ingredient sales grew by 21%, largely due to a 45% increase in purchases from its largest distributor, Ashland Specialty Ingredients, as excess inventory was depleted.
3. United-Guardian's Q1 2026 income was positively impacted by a one-time settlement of $303,133. This income was recognized from a contract manufacturer of Renacidin, related to an unexpected facility shutdown in late 2023 that had resulted in lost sales.
Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →
Stock Movement Drivers
Fundamental Drivers
The 6.5% change in UG stock from 2/28/2026 to 6/27/2026 was primarily driven by a 10.9% change in the company's Net Income Margin (%).| (LTM values as of) | 2282026 | 6272026 | Change |
|---|---|---|---|
| Stock Price ($) | 6.72 | 7.16 | 6.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 10 | 11 | 8.7% |
| Net Income Margin (%) | 19.5% | 21.6% | 10.9% |
| P/E Multiple | 15.8 | 13.9 | -11.7% |
| Shares Outstanding (Mil) | 5 | 5 | 0.0% |
| Cumulative Contribution | 6.5% |
Market Drivers
2/28/2026 to 6/27/2026| Return | Correlation | |
|---|---|---|
| UG | 6.5% | |
| Market (SPY) | 6.6% | -5.5% |
| Sector (XLP) | -5.4% | 6.2% |
Fundamental Drivers
The 28.1% change in UG stock from 11/30/2025 to 6/27/2026 was primarily driven by a 10.9% change in the company's Net Income Margin (%).| (LTM values as of) | 11302025 | 6272026 | Change |
|---|---|---|---|
| Stock Price ($) | 5.59 | 7.16 | 28.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 10 | 11 | 8.7% |
| Net Income Margin (%) | 19.5% | 21.6% | 10.9% |
| P/E Multiple | 13.1 | 13.9 | 6.2% |
| Shares Outstanding (Mil) | 5 | 5 | 0.0% |
| Cumulative Contribution | 28.1% |
Market Drivers
11/30/2025 to 6/27/2026| Return | Correlation | |
|---|---|---|
| UG | 28.1% | |
| Market (SPY) | 7.3% | 8.2% |
| Sector (XLP) | 8.2% | 2.6% |
Fundamental Drivers
The -8.2% change in UG stock from 5/31/2025 to 6/27/2026 was primarily driven by a -14.6% change in the company's Net Income Margin (%).| (LTM values as of) | 5312025 | 6272026 | Change |
|---|---|---|---|
| Stock Price ($) | 7.80 | 7.16 | -8.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 11 | 11 | -4.1% |
| Net Income Margin (%) | 25.3% | 21.6% | -14.6% |
| P/E Multiple | 12.4 | 13.9 | 12.1% |
| Shares Outstanding (Mil) | 5 | 5 | 0.0% |
| Cumulative Contribution | -8.2% |
Market Drivers
5/31/2025 to 6/27/2026| Return | Correlation | |
|---|---|---|
| UG | -8.2% | |
| Market (SPY) | 25.1% | 3.8% |
| Sector (XLP) | 5.1% | -2.3% |
Fundamental Drivers
The -2.7% change in UG stock from 5/31/2023 to 6/27/2026 was primarily driven by a -3.9% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 5312023 | 6272026 | Change |
|---|---|---|---|
| Stock Price ($) | 7.36 | 7.16 | -2.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 11 | 11 | -3.9% |
| Net Income Margin (%) | 21.2% | 21.6% | 1.9% |
| P/E Multiple | 14.0 | 13.9 | -0.6% |
| Shares Outstanding (Mil) | 5 | 5 | 0.0% |
| Cumulative Contribution | -2.7% |
Market Drivers
5/31/2023 to 6/27/2026| Return | Correlation | |
|---|---|---|
| UG | -2.7% | |
| Market (SPY) | 81.3% | 8.3% |
| Sector (XLP) | 26.5% | 2.4% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| UG Return | 22% | -33% | -30% | 41% | -32% | 20% | -35% |
| Peers Return | 34% | -19% | -7% | -3% | -5% | 17% | 9% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 7% | 96% |
Monthly Win Rates [3] | |||||||
| UG Win Rate | 50% | 50% | 42% | 58% | 42% | 50% | |
| Peers Win Rate | 72% | 45% | 50% | 47% | 48% | 63% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| UG Max Drawdown | -21% | -59% | -52% | -40% | -48% | -16% | |
| Peers Max Drawdown | -16% | -31% | -35% | -21% | -29% | -22% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: ASH, IFF, SCL, BCPC, SXT.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 6/26/2026 (YTD)
How Low Can It Go
| Event | UG | S&P 500 |
|---|---|---|
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -28.3% | -9.5% |
| % Gain to Breakeven | 39.6% | 10.5% |
| Time to Breakeven | 14 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -30.6% | -6.7% |
| % Gain to Breakeven | 44.0% | 7.1% |
| Time to Breakeven | 369 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -31.5% | -24.5% |
| % Gain to Breakeven | 46.0% | 32.4% |
| Time to Breakeven | 713 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -33.1% | -33.7% |
| % Gain to Breakeven | 49.6% | 50.9% |
| Time to Breakeven | 69 days | 140 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -11.8% | -17.9% |
| % Gain to Breakeven | 13.4% | 21.8% |
| Time to Breakeven | 21 days | 123 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -43.0% | -53.4% |
| % Gain to Breakeven | 75.4% | 114.4% |
| Time to Breakeven | 223 days | 1085 days |
In The Past
United-Guardian's stock fell 0.0% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 0.0% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | UG | S&P 500 |
|---|---|---|
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -30.6% | -6.7% |
| % Gain to Breakeven | 44.0% | 7.1% |
| Time to Breakeven | 369 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -31.5% | -24.5% |
| % Gain to Breakeven | 46.0% | 32.4% |
| Time to Breakeven | 713 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -33.1% | -33.7% |
| % Gain to Breakeven | 49.6% | 50.9% |
| Time to Breakeven | 69 days | 140 days |
| 2014-2016 Oil Price Collapse | ||
| % Loss | -26.5% | -6.8% |
| % Gain to Breakeven | 36.1% | 7.3% |
| Time to Breakeven | 1362 days | 15 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -43.0% | -53.4% |
| % Gain to Breakeven | 75.4% | 114.4% |
| Time to Breakeven | 223 days | 1085 days |
| Summer 2007 Credit Crunch | ||
| % Loss | -35.2% | -8.6% |
| % Gain to Breakeven | 54.3% | 9.5% |
| Time to Breakeven | 856 days | 47 days |
In The Past
United-Guardian's stock fell 0.0% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 0.0% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About United-Guardian (UG)
United-Guardian, Inc. (UG) is a diversified manufacturer and marketer specializing in a range of proprietary products for both domestic and international markets. The company operates across four distinct business segments: cosmetic ingredients, medical lubricants, pharmaceutical products, and specialty industrial products. This broad product portfolio allows United-Guardian to serve a variety of industries, from personal care and healthcare to specialized industrial applications.
In the cosmetic ingredients segment, UG offers a robust lineup, most notably its LUBRAJEL series of water-based moisturizing and lubricating gel formulations, which include natural and silicone-incorporated options. Other key cosmetic offerings comprise powdered lubricants like B-122, surfactants such as KLENSOFT, and the oil-soluble ORCHID COMPLEX base, all utilized in products like makeup, shampoos, and skin creams. Concurrently, the company is a significant provider of medical lubricants, including various LUBRAJEL formulations (e.g., RR, RC, MG) designed for use with urinary catheters, other medical devices, and oral care products.
Beyond these, United-Guardian develops and markets pharmaceutical products such as RENACIDIN, a prescription drug used to prevent and dissolve urinary calcifications, and CLORPACTIN WCS-90, an antimicrobial agent for treating a range of localized infections. Its industrial product offerings include DESELEX, a sequestering agent for detergent manufacturing, and THOROCLENS, a chlorine-based industrial cleanser. The company also engages in research and development, focusing primarily on cosmetic ingredients, and distributes its products globally through marketing partners, distributors, and wholesalers.
AI Analysis | Feedback
Here are 1-3 brief analogies to describe United-Guardian (UG):
-
A specialized ingredient supplier for the personal care, medical, and industrial sectors, similar to a smaller Croda International.
-
A behind-the-scenes B2B provider of specialized chemicals, lubricants, and niche pharmaceuticals, akin to a focused 3M.
AI Analysis | Feedback
- LUBRAJEL Line (Cosmetic Ingredients): A range of water-based moisturizing and lubricating gel formulations for various cosmetic applications, including natural and silicone-incorporated versions.
- B-122 (Cosmetic Ingredients): A powdered lubricant primarily used in the manufacture of pressed powders, eyeliners, rouges, and industrial products.
- KLENSOFT (Cosmetic Ingredients): A surfactant widely utilized in cosmetic formulations such as shampoos, shower gels, and makeup removers.
- ORCHID COMPLEX (Cosmetic Ingredients): An oil-soluble base incorporated into skin creams, lotions, cleansers, and other cosmetic products.
- LUBRAJEL Medical Lubricants: Water-based lubricant gels designed for use with urinary catheters, pre-lubricated enema tips, oral care, and other medical devices.
- RENACIDIN (Pharmaceuticals): A prescription drug used to prevent and dissolve calcifications in urethral catheters and the urinary bladder.
- CLORPACTIN WCS-90 (Pharmaceuticals): An antimicrobial product used to treat infections in the urinary bladder, localized infections in the peritoneum, and various ear, nose, throat, and sinus infections.
- DESELEX (Industrial Products): A sequestering and chelating agent employed in the manufacturing process of detergents.
- THOROCLENS (Industrial Products): A chlorine-based industrial cleanser.
AI Analysis | Feedback
United-Guardian (UG) primarily sells its products to other companies (B2B) rather than directly to individuals. The provided company description does not list specific names of its major customer companies.
Based on its product lines and marketing channels, United-Guardian's major customers are companies operating in the following sectors, often reached through marketing partners, distributors, and wholesalers:
- Cosmetic Manufacturers: These companies purchase United-Guardian's various cosmetic ingredients, such as the LUBRAJEL line, B-122, KLENSOFT, and ORCHID COMPLEX, to formulate and produce their own finished cosmetic products like moisturizers, makeup, shampoos, and lotions.
- Medical Device Manufacturers, Healthcare Institutions, and Pharmaceutical Distributors: These customers utilize United-Guardian's medical lubricants (e.g., LUBRAJEL RR/RC, MG, LC/FA, FLUID) for various medical devices and oral care products. They also distribute or directly use its pharmaceutical products like RENACIDIN and CLORPACTIN WCS-90.
- Industrial Chemical and Detergent Manufacturers: Businesses that purchase United-Guardian's industrial products such as DESELEX (a sequestering and chelating agent for manufacturing detergents) and THOROCLENS (a chlorine-based industrial cleanser) for their own production processes or for use in industrial settings.
AI Analysis | Feedback
null
AI Analysis | Feedback
Beatriz Blanco, Chief Executive Officer, President, and Director
- Ms. Blanco is responsible for leading United-Guardian, Inc., setting its vision and mission, and driving its growth and profitability. Her role involves making key executive decisions, overseeing all departments, and representing the company to stakeholders, including investors, customers, and the public.
Andrea J. Young, Chief Financial Officer, Treasurer, Controller, Secretary, and Human Resources Manager
- Ms. Young serves as a key financial and administrative leader at United-Guardian, Inc., responsible for the overall financial health and strategy, including financial planning, budgeting, accounting, and managing treasury functions.
- She oversees accounting operations, ensuring accurate financial reporting and compliance.
- She has served as Treasurer and Principal Financial Officer since May 2018, Controller since September 2016, and Secretary since April 2020.
- Prior to her current roles at United-Guardian, Ms. Young held positions as Assistant Controller at Utopia Home Care, Inc., Divisional Financial Controller at Graham Field Health Products, and Audit Manager at Deloitte. She holds a Master of Business Administration degree in Finance and is a CPA.
Donna Vigilante, President and Director
- Ms. Vigilante holds the position of President at United-Guardian, Inc. and was appointed to the Board of Directors in May 2025.
- With over 20 years of experience with the company, she plays a significant role in guiding strategic initiatives and operational execution, overseeing key business functions, and fostering a culture of excellence.
- Her career at United-Guardian includes significant contributions as Vice President and Manager of the Research & Development and microbiology departments, where she was critical in developing the company's natural cosmetic ingredients line.
- Ms. Vigilante holds a Bachelor of Science degree in biochemistry with a minor in business from Stony Brook University.
Kenneth H. Globus, Chairman of the Board of Directors
- Mr. Globus is the Chairman of the Board of Directors for United-Guardian, Inc.
- He is the former President and Chief Executive Officer and remains the controlling shareholder, wielding significant influence over all major corporate actions.
Peter A. Hiltunen, Senior Vice President of Production & Procurement and Production Manager
- Mr. Hiltunen is a seasoned executive responsible for overseeing United-Guardian, Inc.'s manufacturing operations and supply chain.
- He is instrumental in ensuring the efficient and cost-effective production of the company's diverse product portfolio, with responsibilities encompassing raw material sourcing, inventory control, production scheduling, quality assurance, and overall operational efficiency.
AI Analysis | Feedback
The key risks to United-Guardian's business are:
- Revenue Concentration and Product Mix Shift: United-Guardian faces significant risk due to a sharp decline in sales of its higher-margin cosmetic ingredients. This has led to overall margin erosion, despite growth in lower-margin pharmaceutical products like Renacidin and medical lubricants. The company's reliance on a few major distributors, with three accounting for 67% of gross sales in Q1 2025, amplifies this risk, as issues with any single distributor can heavily impact overall revenue.
- Competition and Limited Patent Protection for Core Products: The company operates in highly competitive markets for cosmetic ingredients, pharmaceuticals, and medical lubricants. A significant vulnerability is that a key cosmetic ingredient product, Lubrajel, has been unpatented since 2019. While United-Guardian protects some new work as trade secrets, this offers less robust protection compared to patents, exposing them to competition from lower-cost alternatives, particularly from Asia.
- Small Company Volatility and Limited Diversification: As a nano-cap company with a low market capitalization, United-Guardian is inherently susceptible to high volatility in both its operations and share price. The business also has limited customer and product diversification, making it more vulnerable to adverse market conditions or shifts in demand for its specific niche products. Additionally, modest R&D spending could limit future pipeline momentum and growth opportunities.
AI Analysis | Feedback
null
AI Analysis | Feedback
United-Guardian, Inc. (symbol: UG) operates in several distinct markets for its main products and services, each with a substantial global addressable market size.
Cosmetic Ingredients
The global cosmetic ingredients market was valued at approximately USD 35.27 billion in 2024 and is projected to grow to USD 58.09 billion by 2033, exhibiting a compound annual growth rate (CAGR) of 5.7% during the forecast period (2026–2033).
Medical Lubricants
The global medical lubricant market was estimated to be approximately USD 2.5 billion in 2023 and is projected to reach an estimated value of USD 3.5 billion by 2028.
Pharmaceutical Products
For its pharmaceutical products, such as RENACIDIN and CLORPACTIN WCS-90, the relevant market segments include:
- Genitourinary Drugs: The global genitourinary drugs market size reached USD 33.8 billion in 2024. This market is expected to grow to USD 39.8 billion by 2033, demonstrating a CAGR of 1.8% during the period of 2025-2033.
- Antimicrobial Agents: The global antimicrobial agent market size was valued at USD 3.66 billion in 2024 and is expected to reach USD 7.29 billion by 2032, growing at a CAGR of 9.00% during the forecast period.
Industrial Products
United-Guardian's industrial products, DESELEX and THOROCLENS, address the following global markets:
- Chelating Agents: The global chelating agents market size was valued at USD 7.16 billion in 2024 and is projected to grow to USD 10.02 billion by 2033, with a CAGR of 3.8% during the forecast period (2026–2033).
- Industrial Cleansers: The global industrial cleaning chemicals market was valued at approximately USD 47 billion in 2023 and is projected to grow at a CAGR of over 4.3% between 2024 and 2032.
AI Analysis | Feedback
United-Guardian (UG) is expected to drive future revenue growth over the next 2-3 years through several key initiatives across its diverse product portfolio.
Here are 3-5 expected drivers of future revenue growth:
* **Growth in Pharmaceutical Products, particularly Renacidin**: The pharmaceutical division, with Renacidin as a key product, has shown solid growth, including an 11% increase in gross sales in the first nine months of 2025. A refreshed marketing push for Renacidin is expected to further support future improvements in sales and earnings.
* **Recovery and Expansion in Cosmetic Ingredients**: Despite a temporary setback in the first half of 2025 due to inventory overstock with its largest distributor in Asia, the cosmetic ingredients segment demonstrated a 32% sales increase in fiscal year 2024, driven by regained market share in China. The company is actively working to resolve the inventory situation and expects sales to improve. Additionally, ongoing development of personal care products will contribute to this segment's growth.
* **Increased Sales of Medical Lubricants**: The medical lubricants segment has shown consistent growth, with sales increasing by 12% in the first half of 2025 and 16% in fiscal year 2024, supported by higher demand from a major Chinese contract manufacturer.
* **New Distribution Agreements**: United-Guardian's leadership has highlighted that new distribution agreements are anticipated to support future improvements in sales and earnings across its product lines.
AI Analysis | Feedback
Here's a summary of United-Guardian's capital allocation decisions over the last 3-5 years:
Share Repurchases
- The Board authorized a share repurchase program of up to $5.0 million of the company's common stock on June 10, 2024.
- An additional $2.5 million for share repurchases was authorized on September 26, 2024.
- During the three months ended September 30, 2024, United-Guardian repurchased 801,287 shares of its common stock for approximately $4.8 million.
Share Issuance
- United-Guardian's shares outstanding have remained relatively stable from 2012 to 2025, suggesting no significant share issuances during the last 3-5 years.
Outbound Investments
- In 2024, a significant portion of the net cash used in investing activities, amounting to $7,077,395, was attributed primarily to increased investment in marketable securities.
Capital Expenditures
- United-Guardian's investing cash flow, which includes capital expenditures, was $4,730,000 in 2023, and $897,560 in 2022.
- In 2024, the company had plans for capital expenditures, including upgrading its building sprinkler system and replacing the roof on its facility in Hauppauge, New York.
- For the third quarter of 2025, United-Guardian invested $15,000 in capital expenditures, focusing on funding long-term assets and infrastructure.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| United-Guardian Earnings Notes | 12/16/2025 | |
| With United-Guardian Stock Sliding, Have You Assessed The Risk? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 70.14 |
| Mkt Cap | 4.0 |
| Rev LTM | 1,732 |
| Op Inc LTM | 148 |
| FCF LTM | 107 |
| FCF 3Y Avg | 113 |
| CFO LTM | 189 |
| CFO 3Y Avg | 194 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 0.7% |
| Rev Chg 3Y Avg | -2.7% |
| Rev Chg Q | 5.0% |
| QoQ Delta Rev Chg LTM | 1.2% |
| Op Inc Chg LTM | -17.3% |
| Op Inc Chg 3Y Avg | 5.4% |
| Op Mgn LTM | 10.6% |
| Op Mgn 3Y Avg | 9.6% |
| QoQ Delta Op Mgn LTM | 0.1% |
| CFO/Rev LTM | 12.4% |
| CFO/Rev 3Y Avg | 12.9% |
| FCF/Rev LTM | 7.3% |
| FCF/Rev 3Y Avg | 7.4% |
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Pharmaceuticals | 5 | 5 | 5 | 5 | 6 |
| Cosmetic ingredients | 3 | 5 | 4 | 5 | 7 |
| Medical lubricants | 2 | 2 | 2 | 2 | 2 |
| Industrial and other | 0 | 0 | 0 | 0 | 0 |
| Discounts and allowances | -1 | ||||
| Total | 11 | 12 | 11 | 13 | 14 |
| $ Mil | 2004 | 2003 | 2002 | 2001 | 2000 |
|---|---|---|---|---|---|
| Guardian Laboratories | 4 | 4 | 2 | 3 | 3 |
| Eastern Chemical | -0 | 0 | -0 | 0 | 0 |
| Total | 4 | 4 | 2 | 3 | 3 |
| $ Mil | 2006 | 2005 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|
| Guardian Laboratories | 3 | 3 | 3 | 2 | 2 |
| Eastern Chemical | 0 | 0 | 0 | 0 | 1 |
| Total | 4 | 3 | 3 | 3 | 3 |
Price Behavior
Price Behavior
| Market Price | $7.16 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 03/17/1992 | |
| Distance from 52W High | -20.4% | |
| 50 Days | 200 Days | |
| DMA Price | $7.00 | $6.68 |
| DMA Trend | down | up |
| Distance from DMA | 2.2% | 7.2% |
| 3M | 1YR | |
| Volatility | 31.0% | 36.0% |
| Downside Capture | -34.88 | 6.78 |
| Upside Capture | 12.96 | -2.81 |
| Correlation (SPY) | -9.2% | 3.9% |
UG Betas & Captures as of 5/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | -1.70 | -0.20 | -0.14 | 0.25 | 0.14 | 0.25 |
| Up Beta | -4.41 | -0.24 | 0.21 | 0.13 | 0.10 | 0.07 |
| Down Beta | -0.94 | -1.57 | -0.42 | 0.80 | 0.47 | 0.21 |
| Up Capture | -76% | 11% | -10% | 31% | -3% | 10% |
| Bmk +ve Days | 13 | 28 | 36 | 67 | 141 | 432 |
| Stock +ve Days | 9 | 20 | 31 | 67 | 121 | 359 |
| Down Capture | -133% | -21% | -40% | -23% | 16% | 70% |
| Bmk -ve Days | 7 | 13 | 27 | 57 | 109 | 318 |
| Stock -ve Days | 10 | 17 | 28 | 51 | 120 | 366 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with UG | |
|---|---|---|---|---|
| UG | -9.9% | 36.0% | -0.23 | - |
| Sector ETF (XLP) | 7.8% | 13.1% | 0.31 | -2.4% |
| Equity (SPY) | 21.2% | 12.4% | 1.26 | 3.4% |
| Gold (GLD) | 21.8% | 27.7% | 0.70 | 0.1% |
| Commodities (DBC) | 21.8% | 18.6% | 0.92 | -1.4% |
| Real Estate (VNQ) | 16.1% | 13.6% | 0.85 | -4.3% |
| Bitcoin (BTCUSD) | -44.2% | 42.5% | -1.25 | 1.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with UG | |
|---|---|---|---|---|
| UG | -9.8% | 46.1% | -0.07 | - |
| Sector ETF (XLP) | 7.0% | 13.4% | 0.30 | 6.8% |
| Equity (SPY) | 13.4% | 17.1% | 0.61 | 8.0% |
| Gold (GLD) | 17.8% | 18.3% | 0.79 | 0.1% |
| Commodities (DBC) | 7.4% | 19.5% | 0.28 | 0.4% |
| Real Estate (VNQ) | 3.4% | 18.9% | 0.08 | 8.1% |
| Bitcoin (BTCUSD) | 10.9% | 54.0% | 0.39 | 3.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with UG | |
|---|---|---|---|---|
| UG | -3.2% | 41.4% | 0.06 | - |
| Sector ETF (XLP) | 7.4% | 14.8% | 0.37 | 13.7% |
| Equity (SPY) | 15.2% | 18.0% | 0.72 | 14.4% |
| Gold (GLD) | 11.8% | 16.1% | 0.60 | 0.8% |
| Commodities (DBC) | 5.9% | 18.0% | 0.26 | 3.8% |
| Real Estate (VNQ) | 5.6% | 20.7% | 0.23 | 14.8% |
| Bitcoin (BTCUSD) | 54.7% | 66.4% | 0.95 | 7.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 6/11/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/8/2026 | -1.9% | 2.4% | -1.6% |
| 11/6/2025 | -6.3% | -12.3% | -15.9% |
| 8/8/2025 | -0.5% | -1.0% | 6.4% |
| 5/8/2025 | 0.6% | 1.4% | 3.8% |
| 3/21/2025 | -3.0% | -7.2% | -13.9% |
| 11/8/2024 | -12.1% | -19.3% | -19.2% |
| 8/9/2024 | -2.0% | 7.4% | 23.5% |
| 5/10/2024 | 8.3% | 9.7% | 6.3% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 9 | 11 | 11 |
| # Negative | 14 | 12 | 12 |
| Median Positive | 4.6% | 3.8% | 7.3% |
| Median Negative | -2.9% | -3.4% | -7.0% |
| Max Positive | 27.8% | 22.5% | 36.3% |
| Max Negative | -12.9% | -19.3% | -21.3% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/8/2026 | -1.9% | 2.4% | -1.6% |
| 11/6/2025 | -6.3% | -12.3% | -15.9% |
| 8/8/2025 | -0.5% | -1.0% | 6.4% |
| 5/8/2025 | 0.6% | 1.4% | 3.8% |
| 3/21/2025 | -3.0% | -7.2% | -13.9% |
| 11/8/2024 | -12.1% | -19.3% | -19.2% |
| 8/9/2024 | -2.0% | 7.4% | 23.5% |
| 5/10/2024 | 8.3% | 9.7% | 6.3% |
| 3/22/2024 | 6.1% | 0.9% | 7.3% |
| 11/6/2023 | 27.8% | 22.5% | 36.3% |
| 8/11/2023 | -0.7% | -2.1% | -1.6% |
| 5/11/2023 | -2.7% | -2.9% | -5.3% |
| 3/17/2023 | -12.9% | -8.7% | -8.7% |
| 11/9/2022 | -5.9% | -14.8% | -11.0% |
| 8/12/2022 | -4.4% | -3.8% | -21.3% |
| 5/12/2022 | -10.7% | -0.9% | -1.8% |
| 3/17/2022 | 1.3% | 10.5% | 35.6% |
| 11/10/2021 | 4.6% | 1.4% | 12.7% |
| 8/11/2021 | 1.9% | -0.7% | -2.7% |
| 5/12/2021 | -2.3% | 2.8% | 10.8% |
| 3/19/2021 | 6.4% | -1.8% | 2.3% |
| 11/10/2020 | -0.4% | 3.8% | 5.8% |
| 8/7/2020 | 1.4% | 6.5% | -0.6% |
| SUMMARY STATS | |||
| # Positive | 9 | 11 | 11 |
| # Negative | 14 | 12 | 12 |
| Median Positive | 4.6% | 3.8% | 7.3% |
| Median Negative | -2.9% | -3.4% | -7.0% |
| Max Positive | 27.8% | 22.5% | 36.3% |
| Max Negative | -12.9% | -19.3% | -21.3% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/12/2026 | 10-Q |
| 12/31/2025 | 03/27/2026 | 10-K |
| 09/30/2025 | 11/06/2025 | 10-Q |
| 06/30/2025 | 08/08/2025 | 10-Q |
| 03/31/2025 | 05/13/2025 | 10-Q |
| 12/31/2024 | 03/21/2025 | 10-K |
| 09/30/2024 | 11/12/2024 | 10-Q |
| 06/30/2024 | 08/12/2024 | 10-Q |
| 03/31/2024 | 05/13/2024 | 10-Q |
| 12/31/2023 | 03/22/2024 | 10-K |
| 09/30/2023 | 11/13/2023 | 10-Q |
| 06/30/2023 | 08/11/2023 | 10-Q |
| 03/31/2023 | 05/12/2023 | 10-Q |
| 12/31/2022 | 03/23/2023 | 10-K |
| 09/30/2022 | 11/09/2022 | 10-Q |
| 06/30/2022 | 08/12/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/12/2026 | 10-Q |
| 12/31/2025 | 03/27/2026 | 10-K |
| 09/30/2025 | 11/06/2025 | 10-Q |
| 06/30/2025 | 08/08/2025 | 10-Q |
| 03/31/2025 | 05/13/2025 | 10-Q |
| 12/31/2024 | 03/21/2025 | 10-K |
| 09/30/2024 | 11/12/2024 | 10-Q |
| 06/30/2024 | 08/12/2024 | 10-Q |
| 03/31/2024 | 05/13/2024 | 10-Q |
| 12/31/2023 | 03/22/2024 | 10-K |
| 09/30/2023 | 11/13/2023 | 10-Q |
| 06/30/2023 | 08/11/2023 | 10-Q |
| 03/31/2023 | 05/12/2023 | 10-Q |
| 12/31/2022 | 03/23/2023 | 10-K |
| 09/30/2022 | 11/09/2022 | 10-Q |
| 06/30/2022 | 08/12/2022 | 10-Q |
| 03/31/2022 | 05/13/2022 | 10-Q |
| 12/31/2021 | 03/23/2022 | 10-K |
| 09/30/2021 | 11/12/2021 | 10-Q |
| 06/30/2021 | 08/11/2021 | 10-Q |
| 03/31/2021 | 05/13/2021 | 10-Q |
| 12/31/2020 | 03/22/2021 | 10-K |
| 09/30/2020 | 11/13/2020 | 10-Q |
| 06/30/2020 | 08/11/2020 | 10-Q |
| 03/31/2020 | 05/13/2020 | 10-Q |
| 12/31/2019 | 03/26/2020 | 10-K |
| 09/30/2019 | 11/12/2019 | 10-Q |
| 06/30/2019 | 08/12/2019 | 10-Q |
Industry Resources
| Consumer Staples Resources |
| FoodNavigator |
| Consumer Goods Technology (CGT) |
| Beverage Digest |
| Household Products Resources |
| Happi (Household and Personal Products Industry) |
| Nonwovens Industry |
| Consumer Reports - Household Products |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.
Core Cache Last Updated: 6/27/2026